Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sangamo Therapeutics, Inc.
< Previous
1
2
Next >
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 02, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
March 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
March 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
February 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 05, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 25, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 24, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 08, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
August 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 17, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 29, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 16, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 26, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
April 19, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Tickers
SGMO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.